Skip to main content
Therapeutic Advances in Vaccines and Immunotherapy logoLink to Therapeutic Advances in Vaccines and Immunotherapy
letter
. 2023 Nov 17;11:25151355231213573. doi: 10.1177/25151355231213573

Designing an inclusive immunization schedule for children and adults in India

Farah Niazi 1, Karuna Nidhi Kaur 2, Shazina Saeed 3,, Mohd Shannawaz 4
PMCID: PMC10656793  PMID: 38020959

Immunization plays a pivotal role in upholding public health by effectively preventing the transmission and spread of infectious diseases. By stimulating the body’s immune system to recognize and respond to specific pathogens, vaccines effectively equip individuals with the necessary defenses to combat a wide range of diseases. Through the administration of vaccines according to a well-structured immunization schedule, individuals can develop immunity against various infectious agents, thereby reducing their susceptibility to infection and preventing the onward transmission of diseases within communities. 1 Vaccines have been developed and refined over decades of scientific research and have proven to be highly effective in reducing the burden of infectious diseases worldwide. Diseases that were once widespread, causing significant morbidity and mortality, have been significantly curtailed or even eradicated through successful vaccination campaigns. Examples include smallpox, which was eradicated globally in 1980, and polio, which has seen a remarkable decline in cases due to widespread immunization efforts. 2

Immunization schedules are meticulously designed to ensure optimal protection at different stages of life. India’s national immunization program has made significant strides in reducing the burden of vaccine-preventable diseases. Nevertheless, there is a pressing need to optimize and expand the existing immunization schedule to ensure robust protection across all age cohorts. Presently, the schedule predominantly concentrates on immunizations for infants and children, with relatively limited attention given to adolescents and adults. 3 By extending the immunization schedule to encompass individuals up to the age of 26, India can make substantial progress in mitigating the incidence of vaccine-preventable diseases throughout the population. This expansion will enhance the overall effectiveness of the immunization program and contribute to a healthier nation.

A crucial factor in designing an inclusive immunization schedule is considering the immunological maturity of individuals at different ages. Early infancy is a critical period when newborns possess limited immune protection, making them vulnerable to various infections. Immunizations administered during this period, such as Hepatitis B, BCG, and oral polio vaccines, are crucial in providing early defense against diseases. However, as children grow older, their immune systems evolve, necessitating adjustments to the immunization schedule to sustain optimal protection. Furthermore, adolescents and adults, who may be at increased risk of exposure due to lifestyle factors, occupational hazards, or travel, should also be included in the immunization program to ensure comprehensive immunity. 4

Expanding the immunization schedule to cover individuals up to the age of 26 aligns with the concept of ‘lifelong immunization’ and has several benefits. First, it enhances individual protection by extending the duration of immunity against diseases that may have waning immunity over time. Second, it helps in reducing disease transmission by creating a larger population with immunity, leading to herd immunity. Lastly, it supports the prevention of outbreaks and the potential reintroduction of diseases that were once under control. 5

In light of the unique healthcare challenges faced by India, such as a vast population, diverse geographic regions, and varied socioeconomic backgrounds, an inclusive immunization schedule is imperative. It would serve as a comprehensive framework for healthcare professionals and policymakers, guiding the administration of vaccines across different age groups. In addition, it would facilitate standardized and accessible immunization services, ensuring equitable coverage across urban and rural areas.

The establishment of a comprehensive and inclusive immunization schedule for India, encompassing all age groups from newborns to young adults up to the age of 26, holds immense potential in combating vaccine-preventable diseases. By expanding the existing national immunization program and tailoring it to the specific healthcare needs of India’s population, the country can significantly enhance public health outcomes and contribute to a healthier future for all its citizens. This article aims to propose such a schedule, incorporating the recommended vaccines tailored to different age groups while addressing the unique healthcare requirements of India’s diverse population (Table 1).6,7

Table 1.

Proposed immunization schedule for children and adults in India.

Vaccines Age
Birth to 15 months 16 months to 6 years 7–18 years 19–26 years
Haemophilus influenzae type B vaccine Given at 2, 4, and 6 months of age One dose between this age group Not recommended Not recommended
Hepatitis A vaccine 12 months Up to 23 months Not recommended All adults who have not been vaccinated before, two doses, 6 months apart.
Hepatitis A and hepatitis B vaccine At birth, 1–2 months, 6–18 months Not recommended Not recommended If not vaccinated as a child need to consult the doctor and further proceed.
Hepatitis B vaccine Two doses 6 months apart If not given prior two doses 6 months apart Not recommended All adults who have not been vaccinated before, three doses, over a 6-month period.
Human papillomavirus vaccine Not recommended Not recommended 11 or 12 years to 26 years two doses are recommended for people who get the first dose before age 15. All women who have not been vaccinated before, and men who are at high risk for Human Papilloma Virus (HPV) infection. The HPV vaccine is given as a series of three doses, over a 6-month period.
Influenza vaccine (inactivated) Not recommended One dose annually One dose annually All adults, especially those who are at high risk for complications from influenza, such as older adults, people with chronic health conditions, and pregnant women. Flu vaccine should be given every year seasonal.
Influenza vaccine (live, attenuated) 6 months–8 years 6 months–8 years Up to 8 years two doses every flu season, after one dose in flu season Not recommended for pregnant women, people with certain chronic health conditions or people who are in close contact with people who are at high risk for complications from the flu advised up to 49 years of age.
Influenza vaccine (recombinant) Not recommended Not recommended Not recommended Advised for age group 65 years and above.
Measles, mumps, and rubella vaccine 1 dose at 9–12 months 2nd dose at 16–24 months.
(measles vaccine can be given till 5 years of age)
One dose if not given prior Single dose for all adults who were not vaccinated as children or who do not know their vaccination status.
Meningococcal serogroups A, C, W, Y vaccine Not recommended Not recommended One dose Single dose for all adults who are at high risk for meningococcal disease (college students, military personnel, and people who travel to areas where meningococcal disease is common).
Meningococcal serogroup B vaccine Not recommended Not recommended One dose at any time Single dose for adults at high risk.
Pneumococcal 15-valent conjugate vaccine Two doses, 6–8 weeks apart for children younger than 2 years. One dose for the high-risk group. One dose for high-risk groups includes children with chronic kidney disease, cochlear implants, or asplenia. Those who have not been vaccinated against pneumococcal disease should get one dose of PCV15.
Pneumococcal 20-valent conjugate vaccine Not recommended Not recommended One dose Adults who are at high risk for serious pneumococcal infections, such as those with chronic health conditions or who are older than 65 years.
Pneumococcal 23-valent polysaccharide vaccine Not recommended One dose at 2 years Not recommended Not recommended
Tetanus and diphtheria toxoids 1, 2, and 3 doses at 2, 4, and 6 months 18 months and 4–6 years 4th and 5th doses, respectively. One dose if not given prior The booster dose is given every 10 years from the last vaccination.
Tetanus and diphtheria toxoids and acellular pertussis vaccine Not recommended Not recommended 1 dose at 11–12 years, booster dose every 10 years. Booster dose every 10 years
Varicella vaccine First dose at 12–15 months. 4–6 years second dose Not recommended All adults who have not had chickenpox or who have not been vaccinated against chickenpox.
Zoster vaccine, recombinant Not recommended Not recommended Not recommended All adults aged 50 and older. Two doses, 2–6 months apart.
COVID-19 vaccine Birth to 5 years. Two doses of the Pfizer-BioNTech COVID-19 vaccine, at least 8 weeks apart. Birth to 5 years. Two doses of the Pfizer-BioNTech COVID-19 vaccine, at least 8 weeks apart. For all children even if they got the disease in the past. Age group of 15–18 years. Covaxin only. All adults above 18 years of age. Covishield and Covaxin.

Acknowledgments

None.

Footnotes

Contributor Information

Farah Niazi, Laboratory of Disease Dynamics & Molecular Epidemiology, Amity Institute of Public Health, Amity University, Noida, India.

Karuna Nidhi Kaur, Laboratory of Disease Dynamics & Molecular Epidemiology, Amity Institute of Public Health, Amity University, Noida, India.

Shazina Saeed, Amity Institute of Public Health, Amity University, Noida, Uttar Pradesh 201303, India.

Mohd Shannawaz, Amity Institute of Public Health, Amity University, Noida, India.

Declarations

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Author contributions: Farah Niazi: Conceptualization; Writing – original draft.

Karuna Nidhi: Methodology design; Writing.

Shazina Saeed: Conceptualization; Supervision; Writing – review & editing.

Mohd Shannawaz: Supervision; Writing – review & editing.

Funding: The authors received no financial support for the research, authorship, and/or publication of this article.

The authors declare that there is no conflict of interest.

Availability of data and materials: Not applicable.

References


Articles from Therapeutic Advances in Vaccines and Immunotherapy are provided here courtesy of SAGE Publications

RESOURCES